Publications by authors named "Thomas Nirschl"

Claim this Profile
C
Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity.
Roy Elias, Thomas Nirschl, Michael Rezaee, Anirudh Yerrapragada, Shirley Wang

Cancer Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cytokine Meteorin-like inhibits anti-tumor CD8 T cell responses by disrupting mitochondrial function.
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, John Choi, Aanchal Jain, Thomas R Nirschl

Immunity· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers.
Monali Praharaj, Fan Shen, Alex J Lee, Liang Zhao, Thomas R Nirschl

Cancer Immunol Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Nirmish Singla, Thomas R Nirschl, Aleksandar Z Obradovic, Eugene Shenderov, Kara Lombardo

Sci Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses.
Sahana Jayaraman, Janelle M Montagne, Thomas R Nirschl, Emily Marcisak, Jeanette Johnson

Cell Rep Methods· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.
Aleksandar Obradovic, Casey Ager, Mikko Turunen, Thomas Nirschl, Mohsen Khosravi-Maharlooei

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.
Michael A Gorin, Hiten D Patel, Steven P Rowe, Noah M Hahn, Hans J Hammers, Thomas R Nirschl

Eur Urol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGM4: an immunogenic prostate-restricted antigen.
Zoila A Lopez-Bujanda, Aleksandar Obradovic, Thomas R Nirschl, Laura Crowley, Rodney Macedo

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Max Kates, Thomas R Nirschl, Alex S Baras, Nikolai A Sopko, Noah M Hahn

Eur Urol Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling serum antibodies with a pan allergen phage library identifies key wheat allergy epitopes.
Daniel R Monaco, Brandon M Sie, Thomas R Nirschl, Audrey C Knight, Hugh A Sampson

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
Debebe Theodros, Benjamin M Murter, John-William Sidhom, Thomas R Nirschl, David J Clark

Mol Cell Proteomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Aleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, Alan W Partin, Edward M Schaeffer, Thomas R Nirschl

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Zachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, Robert J Johnston, John J Engelhardt

J Clin Invest· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional profiling of tumor associated macrophages in human renal cell carcinoma reveals significant heterogeneity and opportunity for immunomodulation.
Thomas R Nirschl, Margueritta El Asmar, Wesley W Ludwig, Sudipto Ganguly, Michael A Gorin

Am J Clin Exp Urol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Wendy Mao, Ali Ghasemzadeh, Zachary T Freeman, Aleksandar Obradovic, Matthew G Chaimowitz, Thomas R Nirschl

J Immunother Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Ariel E Marciscano, Ali Ghasemzadeh, Thomas R Nirschl, Debebe Theodros, Christina M Kochel

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.
Michael C Haffner, Diana Taheri, Eddie Luidy-Imada, Doreen N Palsgrove, Marie-Lisa Eich, Thomas R Nirschl

Proc Natl Acad Sci U S A· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Karim Boudadi, Daniel L Suzman, Valsamo Anagnostou, Wei Fu, Brandon Luber, Thomas R Nirschl

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic depletion of lymphocytes following focal radiation to the brain in a murine model.
Anna F Piotrowski, Thomas R Nirschl, Esteban Velarde, Lee Blosser, Sudipto Ganguly

Oncoimmunology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.
Ying-Chun Shen, Ali Ghasemzadeh, Christina M Kochel, Thomas R Nirschl, Brian J Francica

Prostate Cancer Prostatic Dis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Allison M Martin, Christopher J Nirschl, Magda J Polanczyk, W Robert Bell, Thomas R Nirschl

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Yuki Muroyama, Thomas R Nirschl, Christina M Kochel, Zoila Lopez-Bujanda, Debebe Theodros

Cancer Immunol Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical BCG Induces CD4 T-Cell Expansion in an Immune Competent Model of Bladder Cancer.
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel

Cancer Immunol Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Mira A Patel, Jennifer E Kim, Debebe Theodros, Ada Tam, Esteban Velarde, Thomas R Nirschl

J Immunother Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Mira A Patel, Jennifer E Kim, Debebe Theodros, Ada Tam, Esteban Velarde, Thomas R Nirschl

J Immunother Cancer· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis